XIPERE® harnesses the potential pathway known as the SCS®, which spans the circumference of the back of the eye1

The SCS is located between the sclera and the choroid, which is collapsed under normal physiologic conditions. Because it is adjacent to the choroid, drug delivery through the suprachoroidal space has the potential to reach posterior tissues.1-3

A cross-section of the back of the eye the layers that consist of the retina, retinal pigment epithelium, Bruch`s membrane, the choroid, the suprachoroidal space, and the sclera

The SCS® expands, allowing XIPERE® to deliver targeted therapy to the posterior structures of the eye1

The SCS is a natural drainage path from the front to the back of the eye and plays a role in maintaining IOP via aqueous outflow. Upon injection, the SCS expands to accommodate fluid transmission into adjacent tissues.1,2

A cross-section of the back of the eye showing the anatomical changes before, during, and after XIPERE administration Before
A cross-section of the back of the eye showing the anatomical changes before, during, and after XIPERE administration During
A cross-section of the back of the eye showing the anatomical changes before, during, and after XIPERE administration After

Benefits of drug delivery directly through the SCS®

Circumferential and posterior spreading of the drug following injection2

Potential for high bioavailability of drug in the choroid, retinal pigment epithelium (RPE), and retina1

Compartmentalization of drug away from other tissues, potentially resulting in reduced certain side effects1

Targeted

Circumferential and posterior spreading of the drug following injection2

Accessible

Potential for high bioavailability of drug in the choroid, retinal pigment epithelium, and retina1

Contained

Compartmentalization of drug away from other tissues, potentially reducing risk of certain side effects1

Coming Soon: Read the latest publications to learn more about the SCS®

 

Indication

XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.

Important Safety Information

Patients should be monitored following injection for elevated intraocular pressure. See Dosage and Administration instructions in full Prescribing Information.

  • XIPERE is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.
  • XIPERE is contraindicated in patients with known hypersensitivity to triamcinolone acetonide or any other components of this product.
  • Use of corticosteroids may produce cataracts, increased intraocular pressure, and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses, and should be used cautiously in patients with a history of ocular herpes simplex.
  • Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome, and hyperglycemia can occur following administration of a corticosteroid. Monitor patients for these conditions with chronic use.
  • In controlled studies, the most common ocular adverse reactions were increased ocular pressure, non-acute (14%), eye pain, non-acute (12%), cataract (7%), increased intraocular pressure, acute (6%), vitreous detachment (5%), injection site pain (4%), conjunctival hemorrhage (4%), visual acuity reduced (4%), dry eye (3%), eye pain, acute (3%), photophobia (3%), and vitreous floaters (3%), and in 2% of patients: uveitis, conjunctival hyperaemia, punctate keratitis, conjunctival oedema, meibomianitis, anterior capsule contraction, chalazion, eye irritation, eye pruritus, eyelid ptosis, photopsia, and vision blurred.
    The most common non-ocular adverse event was headache (5%).
  • Corticosteroids should be used during pregnancy or nursing only if the potential benefit justifies the potential risk to the fetus or nursing infant.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please click here for full Prescribing Information.

References

  1. Chiang B, Jung JH, Prausnitz MR. The suprachoroidal space as a route of administration to the posterior segment of the eye. Adv Drug Deliv Rev. 2018;126:58-66.
  2. Rai Udo J, Young SA, Thrimawithana TR, et al. The suprachoroidal pathway: a new drug delivery route to the back of the eye. Drug Discov Today. 2015;20(4):491-495.
  3. Moisseiev E, Loewenstein A, Yiu G. The suprachoroidal space: from potential space to space with potential. Clin Ophthalmol. 2016;10:173-178.

Indication

Important Safety Information

XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.

Important Safety Information

Patients should be monitored following injection for elevated intraocular pressure. See Dosage and Administration instructions in full Prescribing Information.

  • XIPERE is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.

Patients should be monitored following injection for elevated intraocular pressure. See Dosage and Administration instructions in full Prescribing Information.